Cargando…
Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we di...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327953/ https://www.ncbi.nlm.nih.gov/pubmed/32306751 http://dx.doi.org/10.1177/1535370220920540 |
_version_ | 1783552659151650816 |
---|---|
author | Jogalekar, Manasi P Veerabathini, Anurag Gangadaran, Prakash |
author_facet | Jogalekar, Manasi P Veerabathini, Anurag Gangadaran, Prakash |
author_sort | Jogalekar, Manasi P |
collection | PubMed |
description | Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we discuss the extent of virus spread, current statistics, SARS-CoV-2 genome organization, comparison between the novel coronavirus and causative agents involved in previous outbreaks, ongoing clinical trials and myths associated with the virus. Lastly, we provide insights into the future perspectives which could prove useful for the scientific community as they work on finding the cure against the disease. IMPACT STATEMENT: Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19. |
format | Online Article Text |
id | pubmed-7327953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73279532020-07-09 Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions Jogalekar, Manasi P Veerabathini, Anurag Gangadaran, Prakash Exp Biol Med (Maywood) Minireview Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we discuss the extent of virus spread, current statistics, SARS-CoV-2 genome organization, comparison between the novel coronavirus and causative agents involved in previous outbreaks, ongoing clinical trials and myths associated with the virus. Lastly, we provide insights into the future perspectives which could prove useful for the scientific community as they work on finding the cure against the disease. IMPACT STATEMENT: Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19. SAGE Publications 2020-04-19 2020-06 /pmc/articles/PMC7327953/ /pubmed/32306751 http://dx.doi.org/10.1177/1535370220920540 Text en © 2020 by the Society for Experimental Biology and Medicine https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Minireview Jogalekar, Manasi P Veerabathini, Anurag Gangadaran, Prakash Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title | Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title_full | Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title_fullStr | Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title_full_unstemmed | Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title_short | Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |
title_sort | novel 2019 coronavirus: genome structure, clinical trials, and outstanding questions |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327953/ https://www.ncbi.nlm.nih.gov/pubmed/32306751 http://dx.doi.org/10.1177/1535370220920540 |
work_keys_str_mv | AT jogalekarmanasip novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions AT veerabathinianurag novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions AT gangadaranprakash novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions |